Incyte (INCY) · povorcitinib
Later window · A neutral label from comparing the two stated windows. It says nothing about the program’s results.
Before
Stated timing: second half of 2025
data in asthma are anticipated in the second half of 2025
· filed · SEC filing
After
Stated timing: 2026
data from the Phase 2 proof-of-concept trial in asthma, are anticipated in 2026
EX-99.1 · filed · SEC filing
Data as of . Both sentences are quoted from the SEC filings linked above and matched to them.
Source: ORION, orionbiotechai.com/changes/INCY-povorcitinib-2025-10-28, data as of Oct 13, 2026
https://www.orionbiotechai.com/changes/INCY-povorcitinib-2025-10-28
Incyte (INCY) pipeline and stated timing · Calendar · Companies A–Z
A Form 10-Q is a company’s quarterly report to the SEC, with unaudited financial statements.